Christopher Boerner is the new CEO of Bristol Myers Squibb, stepping into his role on November 1, 2023. Before this, he held various important positions within the company since joining in 2015, showing a steady rise through roles like Chief...

Christopher Boerner is the new CEO of Bristol Myers Squibb, stepping into his role on November 1, 2023. Before this, he held various important positions within the company since joining in 2015, showing a steady rise through roles like Chief Commercialization Officer and Head of International Markets. Boerner holds a Ph.D. in Economics from Duke University and has a solid background in healthcare strategy. His leadership style focuses on innovation and adaptability, which is crucial in the fast-paced biopharmaceutical industry. In 2023, Boerner's compensation was $1.86 million, with a base salary of $1.5 million and no bonuses as he aims for long-term goals aligned with shareholder interests. Interestingly, he has around $18.9 million worth of stock in Bristol Myers Squibb, which reflects his confidence in the company's future. This stock includes over 101,205 shares and marks a significant portion of his personal wealth. During his time as CEO, Boerner is expected to drive Bristol Myers Squibb towards a path of sustainable growth while continuing to advance their mission of developing innovative therapies that address serious health issues.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Bristol-Myers Squibb CEOs

B

Christopher Boerner

CEO of Bristol-Myers Squibb

Education

Ph.D. in Economics from Duke University

Field of Expertise

Other - Economics

Sector of Economy

Healthcare

Born

March 15, 1971 - 54 years ago

CEO of Bristol-Myers Squibb for

1 year 5 months (Nov 2023 - Present)

Previous Experience

Various senior roles within Bristol-Myers Squibb

Rivals

Competitors/colleagues of Christopher Boerner

P

Albert Bourla

CEO of Pfizer

2023 Compensation

Stock

$0.00

Salary

$1.79M

Bonus

$0.00

Other

$2.26M

Total Holdings

$18.38M

G

Daniel O'Day

CEO of Gilead Sciences

2023 Compensation

Stock

$16.51M

Salary

$1.74M

Bonus

$0.00

Other

$1.22M

Total Holdings

$103.20M

M

Robert M. Davis

CEO of Merck & Co.

2023 Compensation

Stock

$17.72M

Salary

$1.60M

Bonus

$0.00

Other

$386.15K

Total Holdings

$5.80M

J

Joaquin Duato

CEO of Johnson & Johnson

2023 Compensation

Stock

$0.00

Salary

$1.58M

Bonus

$3.65M

Other

$241.99K

Total Holdings

$61.93M

V

Reshma Kewalramani

CEO of Vertex Pharmaceuticals

2022 Compensation

Stock

$10.64M

Salary

$1.40M

Bonus

$3.78M

Other

$43.06K

Total Holdings

$54.25M

A

Robert A. Bradway

CEO of Amgen

2023 Compensation

Stock

$0.00

Salary

$1.79M

Bonus

$0.00

Other

$680.46K

Total Holdings

$182.86M

Holdings

See how much did Christopher Boerner make over time.

As of March 2024, Christopher Boerner holds over 101,205 shares of Bristol Myers Squibb, valued at approximately $18.9 million. This represents a significant part of his financial portfolio, showcasing his strong belief in the company's potential for growth. His holdings...

As of March 2024, Christopher Boerner holds over 101,205 shares of Bristol Myers Squibb, valued at approximately $18.9 million. This represents a significant part of his financial portfolio, showcasing his strong belief in the company's potential for growth. His holdings have seen fluctuations, but as the CEO, Boerner is committed to enhancing shareholder value through smart business strategies. His wealth was at its peak when he was promoted to CEO, reflecting the trust he has in his leadership and the company's direction. Boerner's approach often emphasizes long-term performance over short-term gains, which resonates with investors looking for stability.

Total Stock Sold

$2.04M

BMY

$2.04M

29,532 BMY shares

What if they kept their stock?

If Christopher Boerner didn't sell their stock, today they would have:
Extra BMY29,532 shares worth $1.71M.
This is -16.42% and $335.78K less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Christopher Boerner.

BMY

$110.10K

BMY at $55.05/share

Feb 20, 2025

Purchase

BMY

$99.56K

BMY at $49.78/share

Dec 5, 2023

Purchase

BMY

$150.05K

BMY at $48.86/share

Nov 28, 2023

Purchase

BMY

$2.04M

BMY at $69.20/share

Mar 14, 2022

Sale

BMY

13,417 shares

BMY

Mar 10, 2022

Received

Compensation History

See how much did Christopher Boerner make over time.

In his first year as CEO, Christopher Boerner’s total compensation reached $1,861,636. This includes a base salary of $1.5 million, while his bonus was set at 150% of his salary but went unreceived in 2023, likely due to performance metrics focused on long-term goals. His compensation structure is designed to align with the interests of shareholders, prioritizing sustained company growth over immediate rewards. Other forms of compensation also included additional perks related to financial planning services and executive health programs, adding $311,636 to his earnings. This reflects a broader trend in executive pay where the focus is on longer-term incentives.

Year

2023

Total Compensation

$1.81M

Salary

$1.50M

Board Justification

The compensation philosophy emphasizes performance-based pay that aligns with company performance and shareholder interests, with a significant portion of compensation tied to long-term equity incentives.

Bonus

$0.00

Board Justification

The annual target bonus opportunity for Christopher Boerner is set at 150% of his base salary, reflecting his performance as CEO starting November 1, 2023.

Other

$311.64K

Board Justification

Other compensation includes financial planning services, executive physicals, and contributions to savings plans.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards vested in 2023 as the focus was on performance-based equity awards that will vest in future periods.

Performance Metrics

The performance metrics for the annual incentive plan include Non-GAAP diluted EPS, In-Line and New Product Revenue, New Product Portfolio Revenue, Pipeline performance, and ESG scorecard metrics.

Other Bristol-Myers Squibb CEOs

Here are other CEOs of Bristol-Myers Squibb

Giovanni Caforio

Ex-CEO of Bristol-Myers Squibb

May 2015 - November 2023